

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Vaccine Group Registers Highest 24.4% Value and 32.3% Unit Growth in IPM in Jan 2026: Pharmarack

11 February 2026 | News

Emerging segments such as Urology and Anti-Neoplastics posted double-digit value growth



The Indian Pharmaceutical Market (IPM) recorded monthly sales of Rs 21,208 crore in January 2026, registering a strong 10.2 per cent value growth and 1.8 per cent unit growth, according to PHARMARACK, with super groups continuing to drive market performance.

Cardiac therapies remained the largest contributor, accounting for 14 per cent of IPM value, and delivered a robust 14.0 per cent value growth along with 4.5 per cent unit growth during the month.

Anti-Diabetic therapies contributed 10 per cent to overall IPM value and emerged as one of the fastest-growing large segments, posting a sharp 15.2 per cent value growth supported by 5.5 per cent unit growth. Respiratory therapies, contributing 9 per cent to IPM sales, recorded a value growth of 9.7 per cent with 3.9 per cent unit growth, while Neuro/CNS and Dermatology therapies showed steady momentum with value growth of 10.7 per cent and 9.8 per cent respectively.

Vaccines stood out as the strongest performer among all super groups in January 2026, recording the highest value growth of 24.4 per cent despite a relatively small 1 per cent contribution to IPM value, and significantly outperforming other therapies with an exceptional 32.3 per cent unit growth, indicating sharp demand acceleration.

Other emerging segments such as Urology and Anti-Neoplastics also posted double-digit value growth; however, certain super groups including Gastrointestinal, Pain/Analgesics, Vitamins, Minerals and Nutrition, Hormones and Sexual Health witnessed a decline in unit growth during the month, highlighting selective volume pressure amid an otherwise healthy value-led growth environment.